http://orcid.org/0000-0003-3606-7672
References
- Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–1953.
- Cancer survival in Singapore 1973. 2012. Singapore Cancer Registry. National Registry of Diseases Office; [cited 2020 Feb 29]. Available from: https://www.nrdo.gov.sg/publications/cancer.
- Baas P, Garon EB, Herbst RS, et al. Relationship between level of PD-L1 expression and outcomes in the KEYNOTE-010 study of pembrolizumab vs docetaxel for previously treated, PD-Ll-Positive NSCLC. J Clin Oncol. 2016;34(15_suppl):9015–9015.
- Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–1639.
- Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016;375(19):1823–1833.
- Reck M, Rodriguez-Abreu D, Robinson AG, et al. Updated Analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer With PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019;37(7):537–546.
- Huang M, Lou Y, Pellissier J, et al. Cost effectiveness of pembrolizumab vs. standard-of-care chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in the United States. Pharmacoeconomics. 2017;35(8):831–844.
- Chouaid C, Bensimon L, Clay E, et al. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France. Lung Cancer. 2019;127:44–52.
- Woods B, Sideris E, Palmer S, et al. NICE DSU Technical support document 19: partitioned survival analysis for decision modelling in health care: a critical review. 2017; [cited 2020 Feb 29]. Available from: www.nicedsu.org.uk/wp-content/uploads/2017/06/Partitioned-Survival-Analysis-final-report.pdf.
- Guyot P, Ades AE, Ouwens MJ, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9
- Chouaid C, Agulnik J, Goker E, et al. Health-related quality of life and utility in patients with advanced non-small-cell lung cancer: a prospective cross-sectional patient survey in a real-world setting. J Thorac Oncol. 2013;8(8):997–1003.
- Tan PT, Aziz MIA, Pearce F, et al. Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer’s perspective. BMC Cancer. 2018;18(1):352
- Huang M, Pellissier J, Liao J. A trial-based euroqol EQ-5D health utility analysis in patients with previously treated advanced NSCLC. Value in Health. 2016;19(7):A744.
- Huang M, Pellissier J, Kong F. A trial-based euroqol EQ-5D health utility analysis in patients with previously untreated metastatic NSCLC. Value in Health. 2017;20(5):A115.
- Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer. NICE TA 447. 2017; [cited 2020 Feb 29]. Available from: https://www.nice.org.uk/guidance/ta447.
- Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer. NICE TA531; [cited 2020 Feb 29]. Available from: https://www.nice.org.uk/guidance/ta531.
- Garon EB, Hellmann MD, Rizvi NA, et al. Five-year overall survival for patients with advanced nonsmall-cell lung cancer treated with pembrolizumab: results from the Phase I KEYNOTE-001 study. J Clin Oncol. 2019;37(28):2518–2527.
- Mok T, Wu Y, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819–1830.
- Liao W, Huang J, Hutton D, et al. Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China. J Med Econ. 2019;22(4):344–349.
- Hu X, Goldman DP. First-line pembrolizumab in PD-l1 positive non-small cell lung cancer: a cost-effectiveness analysis from a UK healthcare perspective. Value in Health. 2017;20(9):A399.
- Bhadhuri A, Insinga R, Guggisberg P, et al. Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland. Swiss Med Wkly. 2019;149:w20170.
- Huang M, Lopes G, Insinga R, et al. Cost-effectiveness of pembrolizumab versus chemotherapy as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in the USA. Immunotherapy. 2019;11(17):1463–1478.